# Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

> **NCT06135194** · — · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** T-DXd

## Key facts

- **NCT ID:** NCT06135194
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06135194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06135194, "Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06135194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*